Ofatumumab (HuMax-CD20) in tx-refractory CLL

[Guest guest]

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An

Active Treatment for Patients with CLL Refractory to Both Fludarabine

and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from

the Planned Interim Analysis of An International Pivotal Trial

Monday, December 8, 2008: 11:45 AM

http://ash.confex.com/ash/2008/webprogram/Paper5918.html

n = 138 treated patients (Double refractory, n=59; Bulky fludarabine

refractory, n=79

The bottom line here, as I see it anyway, is a next generation

rituxan-like antibody with low toxicity was active and achieved

responses in this very difficult context: The overall response rate

(ORR) to salvage therapy (of any type) for such patients is

approximately 20%

For Ofatumumab: the overall response rate was 51% in this study.

Also rituxan monotherapy is not often very effective in CLL even in

more favorable circumstances. So this bodes well for Ofatumumab

approval I hope, and it could lead to much better outcomes in CLL

when Ofatumumbab is combined with chemo and used earlier.

--------------------

All the best,

Karl

Patients Against Lymphoma

www.Lymphomation.org